Trulicity Dulaglutide Injection Uses and Mechanisms Of Action

Trulicity Dulaglutide Injection is an agonist of the GLP-1 receptor. In some cases, the drug can cause acute renal failure, or worsen chronic renal failure, and may require hemodialysis. While some adverse reactions were reported in patients with no known renal disease, the majority of patients with adverse reactions also had impaired renal function. Therefore, TRULICITY should be used with caution in patients with renal impairment, and renal function should be monitored periodically.

Trulicity DULAGLUTIDE Injection

Heart rate

A limited number of studies have examined the safety and efficacy of Trulicity Dulaglutide Injection in pregnant women. However, these studies have not been conducted in sufficient numbers to draw definitive conclusions. While the drug is generally safe, the possibility of serious adverse effects, including birth defects, should be considered. This medication should be used with caution, especially in women with poorly controlled diabetes.

Gastric emptying

Despite a variety of potential benefits, the risks associated with Trulicity Dulaglutide Injection are serious. These include increased risk of gastrointestinal adverse reactions, dehydration, and worsening renal function or even the need for hemodialysis. This drug is contraindicated in women who are pregnant or breastfeeding. The risks are heightened in patients with poorly controlled diabetes.

Glycaemic control

Glycaemic control with Trulicity Dulaglutide Injection is recommended for patients with type 2 diabetes and moderate to severe renal impairment. It slows gastric emptying and reduces the absorption of co-administered medications. The delayed gastric emptying was dose-dependent and decreased with escalation of TRULICITY injection to higher doses. The largest delay occurred after the first dose and decreased with subsequent doses.

Thyroid C-cell tumors

Dulaglutide has been approved for use in the treatment of thyroid C-cell tumors. It is a prescription drug that is administered via injection. Although it has been studied in mice and rats, no human studies have been conducted to date. Patients should discuss with their doctors their symptoms and risks of developing a thyroid tumor before beginning treatment with dulaglutide.

Anti-drug antibodies

In a large study, 64 patients with nephrotic syndrome developed anti-drug antibodies to dulaglutide. Forty-four of these patients developed antibodies that neutralized dulaglutide, and the remaining patients developed antibodies that neutralized native GLP-1. The sensitivity and specificity of assays used to detect antibody formation can be influenced by assay methodology, sample handling, and concomitant medications and disease.

Treatment discontinuation

Dulaglutide may be associated with decreased fetal weight, skeletal anomalies, and ossification deficits. In animal studies, it may also cause reduced maternal food consumption and weight. The drug may be contraindicated in patients with multiple endocrine neoplasia type 2 (MEN-2) and thyroid cancer. Among patients with MTC, treatment discontinuation after Trulicity Dulaglutide Injection

Conclusion:

Diabetes is described as a group of metabolic diseases in which the person has high blood glucose (blood sugar). Patients with serious life-threatening Diabetes disease sometimes required medical products that are not yet permitted or available in the country. AlleviareIndia Pharmaceuticals fulfill this need by consulting the choices open to eligible patients to get access to those Diabetes disease Medicine.

  

Comments

Post a Comment

Popular posts from this blog

What Is IDHIFA (Enasidenib)? Causes, Side Effects, Dosage

Image
  WHAT IS IDHIFA (Enasidenib)? IDHIFA Medicine IDHIFA is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if IDHIFA is safe and effective in children. IDHIFA may cause serious side effects, including: Differentiation Syndrome. Differentiation syndrome is a condition that affects your blood cells which may be life-threatening or lead to death if not treated. Differentiation syndrome has happened within 1 day and up to 5 months after starting IDHIFA. Check the following symptoms below. ·          fever ·          cough ·          shortness of breath ·          swelling of arms and legs ·          fast weight gain (greater than 10 pounds within a week) ·          bone pain If you develop any of these symptoms of differentiation syndrome, your healthcare provider may start you on a medicine taken by m
Read more

Hunter Syndrome is Very Rare | Named Patient Program in India

Image
  Hunter Syndrome is an extremely uncommon, acquired hereditary problem brought about by an absent or breaking down compound. In Hunter disorder, the body needs more of the compound iduronate 2-sulfatase. This present compound's responsibility is to separate specific complex particles, and without enough of this protein, the atoms develop in unsafe sums.  The development of enormous measures of these unsafe substances in the long run causes long-lasting, moderate harm influencing appearance, mental turn of events, organ work and actual capacities. Hunter Syndrome is undeniably more normal in young men. The condition is one kind of a gathering of acquired metabolic issues called mucopolysaccharidoses (MPSs). Tracker condition is otherwise called MPS II. Import Elaprase (idursulfase) medicine under named patient program which is commonly use for hunter syndrome.  There's no remedy for Hunter disorder. Treatment includes overseeing side effects and difficulties. Side effects Syndr
Read more

Glyxambi (empagliflozin and linagliptin) Medicine - Uses, Precautions, Indications

Image
What is Glyxambi? Glyxambi (empagliflozin and linagliptin) is a combination of an inhibitor of the sodium-glucose co-transporter (SGLT2) and an inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme as an adjunct to diet and exercise to improve glycemic control. What are the side effects of Glyxambi? Common side effects of Glyxambi include: • urinary tract infection • Common cold symptoms • Upper respiratory tract infection • Genital Yeast Infection • Increased urination • Joint pain • Nausea • runny or stuffy nose • Diarrhea • cough • Elevated blood cholesterol or fat • Diarrhea Glyxambi Dosage The recommended dose of Glyxambi is 10 mg empagliflozin/5 mg linagliptin, taken once daily in the morning, with or without food. In patients who tolerate Glyxambi, the dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily. Do drugs, substances, or supplements interact with Glyxambi? Glyxambi during pregnancy and lactation During pregnancy
Read more